SOURCE: StockCall


December 17, 2010 08:17 ET

Research on Vertex Pharmaceuticals Incorporated and Dynavax Technologies Corporation - FDA Making Life Easier for 'Drug Manufacturers - Other' Sector

JOHANNESBURG, SOUTH AFRICA--(Marketwire - December 17, 2010) - offers investors comprehensive research on the drug manufacturers - other industry and has completed analytical research on Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Dynavax Technologies Corporation (NASDAQ: DVAX). Register with us today at to have free access to these researches. 

The FDA has proven to be more lenient recently as a panel recommended approval of a new obesity drug Contrave. This comes after over a decade has passed since the last drug targeting weight-loss was approved. This should give hope to other drug companies as the market for obesity drugs in the United States is potentially enormous. Currently, 68% of adults are considered overweight, 24% of which are considered obese. is an online platform where investors doing their due-diligence on the drug manufacturers - other industry can have easy and free access to our analyst research and opinions on Vertex Pharmaceuticals Incorporated and Dynavax Technologies Corporation; investors and shareholders of these companies can simply register for a complimentary membership at

Another piece of good FDA related news is their current consideration of a proposal that would allow for faster generic drug reviews. With the growing amount of generic manufacturers moving overseas, the FDA has had a hard time keeping up with inspections. To remedy this, they are considering the payment of fees by manufacturers that would expedite the entire process. Visit to see how companies in this industry have grown over the past years and how they are expected to perform in the future.

While the FDA has been more cordial toward the Drug Manufacturers- Other sector lately, the Federal Trade Commission has been cracking down on pay-for-delay settlements in which brand name drug makers pay generic makers to delay release of their generic version so that the brand named drug maker can continue charging monopoly prices. This practice has been deemed anti-competitive by the FTC due to its harmful effect on consumer pocket books. Register now at to have free access to our reports on the drug manufacturers - other industry.

Taking a look at the financial results delivered during the third quarter by some of the industry players, Vertex Pharmaceuticals Incorporated posted wider loss this quarter due to R&D expenses on its potential blockbuster treatment for hepatitis C which is still in experimental stage. Net loss came in at $209 million on revenue of $23.8 million. On the other hand, Dynavax Technologies Corporation saw its loss for the quarter shrunk to $5 million on revenue of $11.6 million. Investors can register for free to access the research reports on Vertex Pharmaceuticals Incorporated and Dynavax Technologies Corporation at or

About is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information